Albert Labs is a laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies through accelerated regulatory approval pathways.
Stock Performance
Albert Labs News 9 articles
- Albert Labs Announces Private Placement
- Albert Labs signs Letter of Intent (LOI) with iNGENū CRO for First In-Human Clinical Studies
- Albert Labs provides Corporate Update
- Albert Labs Files New International PCT Patent Application for scalable API manufacturing
- Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia
- Albert Labs Granted Health Canada License
- Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species
- Albert Labs Closes $4.7m Private Placement; Begins Trading On The Canadian Securities Exchange
- Albert Labs Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing